A randomized, open-label, multicenter, two-period crossover study to evaluate the 24 hour bronchodilator profile of Tiotropium Bromide Respimat administered once daily versus twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A randomized, open-label, multicenter, two-period crossover study to evaluate the 24 hour bronchodilator profile of Tiotropium Bromide Respimat administered once daily versus twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2015

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 25 Apr 2015 Status changed from recruiting to completed, as reported by European Clinical Trials Database record.
    • 21 Jun 2012 Additional company (Boehringer Ingelheim) added in association as reported by European Clinical Trials Database.
    • 06 Aug 2011 This trial is recruiting in France and has completed in Great Britain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top